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Available online xxxxBackground: Patients with Chagas heart disease (CHD) usually present progressive fatigue and dyspnea. The in-
spiratorymuscleweakness (IMW)may be amarker of exercise intolerance during disease progression. However,
the factors related to IMW in CHD patients still remain unknown.
Methods: Forty-eight CHD patients aged 56.4 (53.3–59.5) years were selected and underwent respiratorymuscle
strength, echocardiography, Cardiopulmonary Exercise Testing and International Physical Activity Questionnaire
(IPAQ). The sample was stratiﬁed according to the percentage (%) of maximum inspiratory pressure (MIP)
achieved in preserved muscle strength (MIP N 70%) or IMW (MIP ≤ 70%). Chi-square and Poisson regression
analysis was performed to verify the predictors of IMW.
Results: The %MIP predicted correlatedwith left ventricular ejection fraction (LVEF), left ventricular end-diastolic
diameter (LVDd) and minute ventilation-carbon dioxide production slope (VE/VCO2 slope). Signiﬁcant differ-
ences in the IPAQ scores (p = 0.036), LVEF (p = 0.020) and VE/VCO2 slope (p = 0.008) were found between
groups with preserved inspiratory muscle strength and with IMW. In multivariate analysis, sedentary patients
and those with reduced LVEF and impaired VE/VCO2 slope had 6.3, 5.5 and 1.2-fold increased risk for IMW,
respectively.
Conclusion: The sedentary lifestyle, reduced LVEF and impaired VE/VCO2 slope showed to be independent predic-
tors of IMW, probably by the association between these variables and the presence of inﬂammation in CHD
patients. The detection of IMWmay be helpful in identifying patients at high risk based on echocardiographic
and functional aspects without much operating costs.





Cardiopulmonary exercise testing1. Introduction
Chagas disease continues to be an important cause of cardiac disease
in many countries of Latin America [1] and it is now an increasing
worldwide problem due to the migration of infected patients to more
developed regions [2]. Approximately 30% of infected patients will
have cardiac damage and 15% will develop severe ventricular dysfunc-
tion [3]. The mortality rate of Chagas heart disease (CHD) with cardiac
dysfunction is approximately 50% in ﬁve years [4]. Moreover, patients
with CHD usually presents with various degrees of heart failure (HF),
fatigue, dyspnea and exercise intolerance [5].
Exercise intolerance, recognized as oneof the factors of poor progno-
sis in HF [6], can be assessed by New York Heart Association (NYHA)
functional class, one of the main prognostic markers in CHD [7], or by, Santo Agostinho, 30.180-100,
osta).
is an open access article under the Cexercise testing, such as Cardiopulmonary Exercise Testing (CPET).
The evaluation of respiratory muscle strength, especially inspiratory
muscle strength, can be a new assessment tool of exercise intolerance
in HF, considering the role of respiratory system during exercise [8].
The inspiratory muscle strength is determined by the maximum in-
spiratory pressure (MIP) during contraction of the inspiratory muscles,
particularly the diaphragm. Inspiratory muscle weakness (IMW) is de-
ﬁned when MIP is signiﬁcantly reduced compared to the predicted
value by gender and age [9].
In HF patients, the prevalence of IMW is estimated in 30–50% [10]
and MIP has been correlated with peak oxygen uptake (VO2peak) [11]
and NYHA functional class [12]. Furthermore, the IMW is considered
an independent predictor of poor prognosis in this population [13]. In
Chagas disease, the predictors and factors related to IMW in the disease
remain unknown.
The evaluation of inspiratory muscle strength is simple, inexpensive
and can be easily implemented in resource-limited areas, especially in
endemic regions of Chagas disease. Therefore, the present study wasC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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IMW in CHD patients.2. Methods
2.1. Study design
This cross-sectional study was conducted between February 2015
and March 2016 at the Referral Outpatient Center for Chagas Disease
at the Clinical Hospital of the Federal University of Minas Gerais
(UFMG), Brazil. The research was carried out in accordance with the
declaration of Helsinki [14] andwas approved by the institutional ethics
committee. All patients gave their written informed consent prior to
participating in the study.
Criteria for inclusion were the diagnosis of Chagas disease deter-
mined by positive speciﬁc serology for Trypanosoma cruzi, clinical, elec-
trocardiographic or echocardiographic ﬁndings compatible with CHD
[15] and stable clinical condition. Exclusion criteria were being smokers
or ex-smokers, the presence of systemic or heart disease by any other
causes and associated comorbidities that could inﬂuence the perfor-
mance in functional evaluations.
The overall study population comprised patientswithin awide spec-
trum of CHD presenting different degrees of cardiac involvement. The
previously selected patients underwent clinical evaluation, respiratory
muscle strength testing, echocardiography and Cardiopulmonary Exer-
cise Testing. The evaluations were performed at the same time on each
day. After all blinded evaluations, patients were stratiﬁed according to
the presence of IMW.2.2. Respiratory muscle strength testing
Respiratory muscle strength was determined with a previously
calibrated aneroid vacuum manometer (GERAR, São Paulo, Brazil) and
values expressed in cmH2O. MIP was evaluated through a mouthpiece
in deep inspiration from functional residual capacity [9,16]. To deter-
mine the maximal expiratory pressure (MEP), subjects were instructed
to perform a maximal expiratory effort from the total lung capacity [9].
In both MIP and MEP evaluation, the highest value of three measure-
ments was considered.
The values are shown in absolute and relative values by the percent-
age achieved compared to the predicted by age and gender [17]. Pa-
tients were classiﬁed as with IMW when MIP was less than 70% of
predicted [10,16].2.3. Functional and echocardiography evaluation
The Cardiopulmonary Exercise Testing (CPET), the gold-standard in
functional capacity evaluation, was carried out on a treadmill (Centuri-
on 200, Micromed®, Brasilia, Brazil) by ramp protocol with the meta-
bolic analysis system (MetaLyzer® 3B Cortex-Leipzig, Germany). The
VO2peak, peak oxygen uptake at anaerobic threshold (VO2peak at AT),
minute ventilation-carbon dioxide production slope (VE/VCO2 slope)
and percentage of maximal heart rate achieved (%HR) were considered
for functional evaluation according to current guidelines [18].
To assess the physical activity level, the International Physical Activ-
ity Questionnaire (IPAQ) was applied. Validated in 12 countries [19],
IPAQ is a questionnaire that allows estimating the time spent weekly
in physical activity and classify the physical level in sedentary (score
1), moderate active (score 2) or physically active (score 3) individuals.
The echocardiography techniques and calculations of different cardi-
ac dimension and volumes were performed according to the recom-
mendations of the American Society of Echocardiography [20]. Left
ventricular ejection fraction (LVEF) was calculated according to the
modiﬁed Simpson's rule.2.4. Statistical analysis
GPower software (G*Power forWindows, version 3.1.7)was used to
detect a prevalence ratio of 1.7 increased risk of sedentary patients in
develop IMW, based on a pilot study. Considering an alpha error of
0.05 and statistical power of 95%, a total of 48 patients was obtained.
Datawere analyzedwith SPSS (SPSS forWindows, version 17.0). The
data distribution was veriﬁed by Kolmogorov-Smirnov test. The de-
scriptive analysis was shown as mean and 95% conﬁdence interval and
categorical variables are presented as absolute number (percentage).
Spearman Rank correlation test, Chi-square, Independent T-test and
Mann-Whitney were performed for data analysis, with signiﬁcance
levels at 0.05.
To verify the predictors of IMW, the Chi-square test was used in the
univariate analysis. The following variables were categorized: gender
(male and female); NYHA (I, II and III); IPAQ score (1, 2 and 3); expira-
tory muscle weakness [17] (MEP ≤ 70% of predicted); LVEF [21] in nor-
mal (≥50%) and reduced (b50%); left ventricular end-diastolic diameter
(LVDd) in normal (≤50 mm) and abnormal (N50 mm); VO2peak [22] in
normal (N20 mL.kg.min) and functional impairment (≤20 mL.kg.min);
%HR achieved in low-to-moderate (b80% of maximumHR) and high in-
tensity effort (≥80% ofmaximumHR) and,ﬁnally, VE/VCO2 slope [23] in
normal (b32.5) and impaired (≥32.5).
For the multivariate analysis, Poisson regression was performed to
determine the prevalence ratio (PR) with the variables that showed a
p-value b0.15 in the univariate analysis.
3. Results
3.1. Characteristics of the sample
A total of 108 CHD patients were selected. Of these, ﬁfty patients
(46%) were excluded for having a comorbid condition, such as systemic
arterial hypertension (n = 26), diabetes mellitus (n = 7), thyroid dys-
function (n=9) and lower extremity osteoarthritis (n=8). Another 10
patients (9%)were excluded because theywere smokers or ex-smokers.
Thus, 48 patients fulﬁlled the inclusion criteria of the present study.
Clinical and demographic characteristics, echocardiographic parameters
and functional variables in the overall study population are shown in
Table 1.
The %MIP predicted correlated weakly with LVEF (r = 0.423; p =
0.007), LVDd (r = −0.380; p = 0.017) and VE/VCO2 slope
(r =−0.446; p = 0.004) as demonstrated in Fig. 1.
The inspiratory muscle weakness was veriﬁed in 17 patients (35%).
Signiﬁcant differences in IPAQ score, LVEF and VE/VCO2 slope were
found between groups with preserved inspiratory muscle strength
and with IMW (Table 2).
In the univariate model, the IMW was signiﬁcantly associated with
lower IPAQ score (p= 0.036), reduced LVEF (p= 0.007) and abnormal
LVDd (p = 0.029) but not with age (p = 0.900), gender (p = 0.489),
worse NYHA functional class (p = 0.132), expiratory muscle weakness
(p = 0.193), functional impairment by VO2peak (p = 0.846), impaired
VE/VCO2 slope (p = 0.135) and %HR achieved (p= 0.757). In the mul-
tivariate model, it was found that patients with sedentary lifestyle, re-
duced LVEF and impaired VE/VCO2 slope had, respectively, a 4.3, 5.5
and 1.2-fold increased risk for IMW (PR 4.3, 95% CI 2.3 to 6.6,
p b 0.001; PR 5.5, 95% CI 1.9 to 11.9, p = 0.002, PR 1.2, 95% CI 1.1 to
1.5, p = 0.001, respectively) (Table 3).
4. Discussion
To the best of our knowledge, the present study is the ﬁrst that
showed the functional differences in CHD patients with IMW when
compared to those with preserved strength. Our results demonstrated
that the sedentary lifestyle, reduced LVEF and impaired VE/VCO2 slope
were independent predictors of IMW in CHD patients. The coexistence
Table 1
Characteristics of the patients (n = 48).
Variables Mean (95% CI) or n (%)
Age (years) 56.4 (53.3–59.5)
















LVEF (%) 54.3 (48.6–59.9)
LVDd (mm) 55.7 (51.9–59.5)
VO2peak (mL.kg.min) 20.4 (18.8–22.0)
VO2 at AT (mL.kg.min) 15.9 (14.7–17.0)
VE/VCO2 slope 22.8 (19.7–25.9)
Peak HR (% predicted) 81.9 (77.3–86.6)
Data presented as mean and 95% conﬁdence interval (95% CI) or number (percentage).
NYHA = New York Heart Association functional class; LVEF = left ventricular ejection
fraction; LVDd= left ventricular end-diastolic diameter; VO2peak=peakoxygenuptake;
VO2 at AT = oxygen uptake at anaerobic threshold; VE/VCO2 slope = minute ventila-
tion-carbon dioxide production slope; Peak HR = percentage of maximum heart rate
achieved.
Fig. 1. Correlation analysis between percentage of maximum inspiratory pressure (MIP)
achieved and A) left ventricular ejection fraction, B) left ventricular end-diastolic
diameter and C) minute ventilation-carbon dioxide production slope.
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tients emphasizes the need to evaluate inspiratory muscle strength in
the periodic assessment of these patients and the stimulation of early
change of lifestyle. In addition, the presence of IMWmay be helpful in
identifying patients at high risk based on echocardiographic and func-
tional parameters without many operating costs.
We hypothesize that the inﬂammatory process present in CHD can
be the central role of interaction among IMW, physical inactivity and
systolic dysfunction. In heart failure patients, there was an increase in
proportion of ﬁbers type I and IIa and a decrease in ﬁbers type IIb in di-
aphragm [24], which are easily fatigued. In fact, diaphragmatic work is
increased in HF patients both at rest and during exercise compared to
healthy individuals, leading to an exaggerated ventilatory response
and consequent increase in the physiological dead space [25,26].
The presence of inﬂammatory process, especially the higher expres-
sion of tumor necrosis factor alpha (TNF-α) seems to be themain factor
of modiﬁcation of diaphragmatic muscle ﬁbers. The increase of myocar-
dial overload stimulates TNF-α release [27], which will act on the dia-
phragm, leading to atrophy of myosin ﬁbers and, consequently, to a
decrease in diaphragmatic contractility [26,28]. Thus, it is expected
that patients with systolic dysfunctionmay also develop IMW, especial-
ly in CHD, characterized by intense inﬂammatory process.
Sousa et al. [29] veriﬁed that asymptomatic Chagas disease patients
had signiﬁcantly higher inﬂammatory cytokine expression, such as in-
terferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and in-
terleukin 6 (IL-6) compared to healthy individuals. Moreover, they
also reported that patients with Chagas cardiomyopathy with dilated
left ventricle and impaired ventricular systolic function had higher con-
centrations of inﬂammatory cytokine comparedwith both healthy indi-
viduals and asymptomatic Chagas disease patients. To conﬁrm our
hypothesis, further studies are necessary to compare the inﬂammatory
cytokine expression and MIP in CHD patients.
We also demonstrated that the sedentary lifestyle is a strong predic-
tor of IMW, independently of other clinical variables. It is well
established that exercise at moderate to high intensity signiﬁcantly re-
duces the circulating levels of TNF-α [30], one responsible for IMW. A
recent systematic review [31] reported that exercises with frequency
Table 2
Differences in variables between groups stratiﬁed according to the inspiratory muscle
strength.
Variables Patients with preserved
inspiratory muscle
strength (n = 31)
Patients with
inspiratory muscle
weakness (n = 17)
p-value
Age (years) 56.4 (52.7–60.1) 56.9 (51.3–63.5) 0.889
Gender (F/M) 23/8 11/6 0.489
NYHA I (20); II (10); III (1) I (7); II (7); III (3) 0.132
IPAQ 1 (3); 2 (13); 3 (15) 1 (7); 2 (5); 3 (5) 0.036
%MEP predicted 83.4 (68.5–98.3) 72.38 (63.7–81.0) 0.154
LVEF (%) 58.5 (55.1–64.4) 46.9 (38.6–52.7) 0.020
LVDd (mm) 53.4 (49.2–57.5) 59.0 (53.6–64.4) 0.097
VO2peak (mL.kg.min) 21.1 (18.9–23.4) 20.2 (17.5–22.8) 0.459
VO2 at AT (mL.kg.min) 16.5 (15.1–17.8) 15.7 (13.4–17.9) 0.517
VE/VCO2 slope 20.4 (17.7–23.2) 28.2 (22.1–34.3) 0.008
Peak HR (%predicted) 83.5 (78.3–88.7) 84.0 (75.4–92.7) 0.900
Data presented as mean and 95% conﬁdence interval (95% CI) or number (percentage).
NYHA = New York Heart Association functional class; %MIP predicted = percentage of
maximal inspiratorymuscle strength achieved; %MEP predicted=percentage ofmaximal
expiratory muscle strength achieved; LVEF = left ventricular ejection fraction; LVDd =
left ventricular end-diastolic diameter; VO2peak = peak oxygen uptake; VO2 at AT= oxy-
gen uptake at anaerobic threshold; VE/VCO2 slope = minute ventilation-carbon dioxide
production slope; Peak HR = percentage of maximum heart rate achieved. The values
highlighted in bold are statistically signiﬁcant (p b 0.05).
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levels of TNF-α in HF patients. In the present study, sedentary CHD pa-
tients have similar risks of developing IMW compared to those moder-
ately active and the risk in sedentary patients is almost threefold
elevated than in physically active patients.
The expiratory muscle strength was also lower than the predicted,
which is consistent with generalized muscle weakness presented by
CHD patients, especially in those with dilated cardiomyopathy [32].
Previous study [33] demonstrated the signiﬁcant correlation be-
tween MIP and VO2peak in cardiac patients. But in the present study,
among the functional variables evaluated by CPET, the only one that
was signiﬁcantly different between the groups with and without IMW
was the VE/VCO2 slope, also an independent predictor of IMW. The
VE/VCO2 slope represents the patient's ventilatory inefﬁciency, espe-
cially the difﬁculty in removing carbon dioxide and is related to
the ventilation-perfusion abnormalities [34], such as the presence ofTable 3
Independent predictors of IMW in the study population in multivariate model.
N (%) PR 95% CI p-value
NYHA
III 4 (8%) 1 Reference
II 17 (36%) 0.997 0.297 to 3.339 0.996
I 27 (56%) 0.397 0.108 to 1.466 0.166
IPAQ
Active 20 (42%) 1 Reference
Moderate 18 (37%) 1.685 0.676 to 4.197 0.263
Sedentary 10 (21%) 4.319 2.271 to 6.581 b0.001
EMW
Preserved 27 (56%) 1 Reference
Weakness 21 (44%) 1.404 0.673 to 2.929 0.366
VE/VCO2 slope
Normal 40 (83%) 1 Reference
Impaired 8 (17%) 1.178 1.062 to 1.515 0.001
LVEF
Preserved 31 (64%) 1 Reference
Reduced 17 (36%) 5.529 1.913 to 11.861 0.002
LVDd
Normal 26 (54%) 1 Reference
Abnormal 22 (46%) 0.587 0.169 to 2.033 0.401
PR= prevalence ratio; 95% CI= 95% conﬁdence interval; NYHA=New York Heart Asso-
ciation; IPAQ= International Physical Activity Questionnaire; EMW= expiratory muscle
weakness; LVEF= left ventricular ejection fraction; LVDd = left ventricular end-diastolic
diameter; VE/VCO2 slope = minute ventilation-carbon dioxide production slope. The
values highlighted in bold are with statistical signiﬁcance (p b 0.05).inﬂammation and tissue ﬁbrosis, common clinical ﬁndings in CHD [5,
35]. Recently, other functional variables evaluated by CPET have gained
prognostic signiﬁcance [36] and the relationship between IMW and
these variables should be investigated.
Baiao et al. [37] evaluated 15 patients with Chagas cardiomyopathy
(50.27±5.68 years;NYHA II/III) and lower values in the %MIPpredicted
compared to the healthy group (p=0.005) were observed. The authors
also reported the correlation between MIP and VO2peak (r = 0.52;
p b 0.001). In contrast, the present study did not ﬁnd a signiﬁcant corre-
lation between MIP and VO2peak and two points can explain the differ-
ence. First, the functional capacity in our study was directly evaluated
by gas analysis, which is the most accurate tool for determining the
VO2peak, while Baiao et al. [37] used the estimated VO2. Second, the pres-
ent study veriﬁed the physical level of the patients and Baiao et al. [37]
did not mention the patient's physical activity proﬁle.
The study limitations include the small number of patients with se-
vere functional impairment, sincemost of the patientswere in function-
al class I. In addition, patients were on medication that could improve
the performance on functional tests and can inﬂuence some variables,
such as the peak heart rate achieved during the CEPT. However, due to
ethical reasons, we decided not to discontinue drug use during the
study period, as these medications are essential for the management
of patients with left ventricular dysfunction.
The results of the present study have great clinical importance be-
cause Chagas disease patients often come from resource-limited areas
without sophisticated equipment, where echocardiography and CPET
are generally not available. Left ventricular systolic function is a well-
established prognostic marker of the risk of death in Chagas disease
[38] and the VE/VCO2 slope is considered the only independent predic-
tor of mortality among functional variables measured at CPET [23]. The
close relationship between IMW with reduced LVEF and impaired VE/
VCO2 slope can assist in risk stratiﬁcation of patients using inexpensive
methods. We also emphasize the early incentive to exercise in CHD and
the need to evaluate the inspiratory muscle strength in this population.
5. Conclusion
Lower physical levels, LVEF and higher ventilatory inefﬁciency by
VE/VCO2 slope were independent predictors of IMW in CHD patients,
probably by the presence of intense inﬂammatory process in this
population.
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